Chromium(III) picolinate

Last updated
Chromium(III) picolinate
Chromium picolinate.png
Ball and Stick model of chromium (III) picolinate Chromium(III) picolinate 3D ball.png
Ball and Stick model of chromium (III) picolinate
Spacefill model of chromium (III) picolinate Chromium(III) picolinate 3D spacefill.png
Spacefill model of chromium (III) picolinate
Names
IUPAC name
Tris(picolinate)chromium(III)
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
ECHA InfoCard 100.131.423 OOjs UI icon edit-ltr-progressive.svg
PubChem CID
UNII
  • InChI=1S/3C6H5NO2.Cr/c3*8-6(9)5-3-1-2-4-7-5;/h3*1-4H,(H,8,9);/q;;;+3/p-3 Yes check.svgY
    Key: CBDQOLKNTOMMTL-UHFFFAOYSA-K Yes check.svgY
  • InChI=1/3C6H5NO2.Cr/c3*8-6(9)5-3-1-2-4-7-5;/h3*1-4H,(H,8,9);/q;;;+3/p-3
    Key: CBDQOLKNTOMMTL-DFZHHIFOAM
  • ionic form:c1ccnc(c1)C(=O)[O-].c1ccnc(c1)C(=O)[O-].c1ccnc(c1)C(=O)[O-].[Cr+3]
  • coordination form:c0ccc[n+]1c0C(=O)O[Cr-3]123(OC(=O)c0[n+]2cccc0)OC(=O)c0[n+]3cccc0
Properties
Cr(C6H4NO2)3
Molar mass 418.33 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Yes check.svgY  verify  (what is  Yes check.svgYX mark.svgN ?)

Chromium(III) picolinate is a chemical compound with the formula Cr(C5H4N(CO2H))3, commonly abbreviated as CrPic3. It is sold as a nutritional supplement to treat type 2 diabetes and promote weight loss. [1] This bright-red coordination compound is derived from chromium(III) and picolinic acid. Trace amounts (25-35 mcg [2] ) of chromium are needed for glucose utilization by insulin in normal health, but deficiency is extremely uncommon and has been observed usually in people receiving 100% of their nutrient needs intravenously, i.e., total parenteral nutrition diets. [3] Chromium has been identified as regulating insulin by increasing the sensitivity of the insulin receptor. [4] As such, chromium(III) picolinate has been proposed as a treatment for type 2 diabetes, although its effectiveness remains controversial due to conflicting evidence from human trials. [5]

Contents

History

A study in 1989 suggested that chromium(III) picolinate may assist in weight loss and increase muscle mass which led to an increase in the usage of chromium(III) picolinate supplements, resulting in it being for a while the second most widely used supplement behind calcium. [5] A 2013 Cochrane review was unable to find "reliable evidence to inform firm decisions" to support such claims. [6] Research has generally shown that it improves insulin sensitivity by either prolonging its activity or up-regulating the production of mRNA to produce more insulin receptors.[ citation needed ]

Amongst the transition metals, Cr3+ is the most controversial in terms of nutritional value and toxicity. [7] This controversy centers on whether Cr3+ provides any nutritional benefits. [7] [8] Furthermore, this controversy is amplified by the fact that no Cr-containing biomolecules have had their structure characterized, nor has the mode of action been determined. The first experiment that led to the discovery of Cr3+ playing a role in glucose metabolism proposed that the biologically active form of the metal existed in a protein called glucose tolerance factor , however, new evidence suggests that it is simply an artifact obtained from isolation procedures. [5] [7] [9] [10] The only accepted indicator of chromium deficiency is the reversal of symptoms that occurs when chromium(III) supplementation is administered to people on total parenteral nutrition. [11]

Physicochemical properties

Watch glass with two grams of chromium(III) picolinate Chromax II.JPG
Watch glass with two grams of chromium(III) picolinate
Skeletal stick model (hydrogen atoms omitted) of the chromium(III) picolinate complex Chromium(III) picolinate 3D skeletal.png
Skeletal stick model (hydrogen atoms omitted) of the chromium(III) picolinate complex
Rotating video file of chromium picolinate coordination chemistry and molecular geometry Chromium picolinate3.gif
Rotating video file of chromium picolinate coordination chemistry and molecular geometry

Chromium(III) picolinate is a pinkish-red compound and was first reported in 1917. [5] [12] It is poorly soluble in water, having a solubility of 600 μM in water at near neutral pH. [8] Similar to other chromium(III) compounds, it is relatively inert and unreactive, meaning that this complex is stable at ambient conditions and high temperatures are required to decompose the compound. [13] At lower pH levels, the complex hydrolyzes to release picolinic acid and free Cr3+. [8]

Structure

Chromium(III) picolinate has a distorted octahedral geometry and is isostructural to cobalt (III) and manganese (III) counterparts. [14] [15] Chromium(III) is a hard lewis acid and as such has high affinity to the carboxylate oxygen and medium affinity to the pyridine nitrogen of picolinate. [14] [16] Each picolinate ligand acts as a bidentate chelating agent and neutralizes the +3 charge of Cr3+. Evidence that the Cr3+ center coordinates to the pyridine nitrogen comes from a shift in the IR spectra of a C=N vibration at 1602.4 cm−1 for free picolinic acid to 1565.9 cm−1 for chromium(III) picolinate. [14] The bond length between Cr3+ and the nitrogen atom of the pyridine ring on picolinate ranges from 2.047 to 2.048 Å. [15] The picolinate ligand coordinates to Cr3+ only when deprotonated and this is evident by the disappearance of IR bands ranging from 2400 to 2800 cm−1 (centered at 2500 cm−1) and 1443 cm−1, corresponding to the O-H stretching and bending, respectively, on the carboxyl functional group. [13] [14] Furthermore, this IR shift also indicates that only one oxygen atom from the carboxylate of picolinate coordinates to the Cr3+ center. [13] [14] [16] The Cr-O bond length ranges from 1.949 to 1.957 Å. [15] The crystal structure has only been recently described in 2013. [16] Water does not coordinate to the Cr3+ center and is instead thought to hydrogen bond between other Cr(Pic)3 complexes to form a network of Cr(Pic)3 complexes. [16]

Biochemistry of chromium(III) picolinate

Chromium has been identified as an essential nutrient in maintaining normal blood glucose levels and as such, it is proposed to interact with two naturally occurring molecules found within the body. [9] These interactions are most likely to occur through coordination with hard ligands such as aspartate and glutamate, as Cr(III) itself is a hard metal.

Absorption and excretion of chromium(III) picolinate

Once chromium(III) picolinate is ingested and enters the stomach, acidic hydrolysis of the complex occurs when in contact with the stomach mucosa. [17] The hydrolyzed Cr3+ is present in the hexaaqua form and polymerizes to form an insoluble Cr(III)-hydroxide-oxide (the process of olation) once it reaches the alkaline pH of the small intestine. [18] Approximately 2% of Cr3+ is absorbed through the gut as chromium(III) picolinate via unsaturated passive transport. [12] Although absorption is low, CrPic3 absorbs more efficiently than other organic and inorganic sources (i.e. CrCl3 and chromium nicotinate) and thus accumulate at higher concentrations in tissues. [10] [19] This has been one major selling point for chromium(III) picolinate over other chromium(III) supplements. Organic sources tend to absorb better as they have ligands which are more lipophilic and usually neutralize the charge of the metal, thus permitting for easier passage through the intestinal membrane. [19]

It has also been shown that dietary factors affect Cr3+ absorption. Starch, simple sugars, oxalic acid, and some amino acids tend to increase the rate of absorption of chromium(III). This is a result of ligand chelation, converting hexaaqua Cr3+ into more lipophilic forms. [19] In contrast, calcium, magnesium, titanium, zinc, vanadium, and iron reduce the rate of absorption. [19] Presumably, these ions introduce new metal-ligand equilibria, thus decreasing the lipophilic ligand pool available to Cr3+. Once absorbed into the bloodstream, 80% of the Cr3+ from CrPic3 is passed along to transferrin. [17] [19] [20] The exact mechanism of release is currently unknown, however, it is believed not to occur by a single electron reduction, as in the case of Fe3+, due to the high instability of Cr2+. [18] Administered Cr3+ can be found in all tissues ranging from 10 to 100 μg/kg body weight. [19] It is excreted primarily in the urine (80%) while the rest is excreted in sweat and feces. [19]

Binding of chromium(III) to transferrin

The 2 binding sites of transferrin. When iron saturation is high, Cr can compete with Fe for binding to the C-lobe. Transferrin binding sites.png
The 2 binding sites of transferrin. When iron saturation is high, Cr can compete with Fe for binding to the C-lobe.

Transferrin, in addition to chromodulin has been identified as a major physiological chromium transport agent, [20] [22] although a recent study found that Cr3+ in fact disables transferrin from acting as a metal ion transport agent. [23] While transferrin is highly specific for ferric ions, at normal conditions, only 30% of transferrin molecules are saturated with ferric ions, allowing for other metals, particularly those with a large charge to size ratio, to bind as well. [8] [12] [21] The binding sites consist of a C-lobe and an N-lobe which are nearly identical in structure. [21] Each lobe contains aspartic acid, histidine, 2 tyrosine residues and a bicarbonate ion that acts as a bidentate ligand to allow iron or other metals to bind to transferrin in a distorted octahedral geometry. [20] [21] [22] Evidence supporting the binding of Cr3+ to transferrin comes from extensive clinical studies that showed a positive correlation between levels of ferritin and of fasting glucose, insulin, and glycated hemoglobin (Hb1Ac) levels. [8] Furthermore, an in vivo study in rats showed that 80% of isotopically labelled Cr3+ ended up on transferrin while the rest were bound to albumin. An in vitro study showed that when chromium(III) chloride was added to isolated transferrin, the Cr3+ readily bound transferrin, owing to changes in the UV-Vis spectrum. [12] [20] [24] The formation constant for Cr3+ in the C-lobe is 1.41 x 1010 M−1 and 2.04 x 105 M−1 in the N-lobe, which indicates that Cr3+ preferentially binds the C-lobe. [8] [20] [21] Overall, the formation constant for chromium(III) is lower than that of the ferric ion. [20] The bicarbonate ligand is crucial in binding Cr3+ as when bicarbonate concentrations are very low, the binding affinity is also significantly lower. [20] Electron paramagnetic resonance (EPR) studies have shown that below pH 6, chromium(III) binds only to the N-lobe and that at near neutral pH, chromium(III) binds to the C-lobe as well. [8] Chromium(III) can compete with the ferric ion for binding to the C-lobe when the saturation greatly exceeds 30%. [21] As such, these effects are only seen in patients with hemochromatosis, an iron-storage disease characterized by excessive iron saturation in transferrin. [24]

Mechanism of action

This diagram shows the insulin pathway and its role in regulating blood glucose levels Regulation of glycogen metabolism insulin.svg
This diagram shows the insulin pathway and its role in regulating blood glucose levels

Low-molecular-weight chromium-binding substance (LMWCr; also known as chromodulin) is an oligopeptide that seems to bind chromium(III) in the body. [25] It consists of four amino acid residues; aspartate, cysteine, glutamate, and glycine, bonded with four (Cr3+) centers. [8] [11] [26] It interacts with the insulin receptor, by prolonging kinase activity through stimulating the tyrosine kinase pathway, thus leading to improved glucose absorption. [20] [27] It has been confused with glucose tolerance factor. Despite recent efforts to characterize chromodulin, the exact structure is still relatively unknown. [28]

Although chromodulin's exact mechanism of action on the insulin receptor is currently unknown, one commonly described mechanism is presented below. This proposed mechanism has the highest amount of agreement with various experiments involving chromodulin. [7] [12] [18] [24]

Normally, chromodulin exists in the apochromodulin form, which is free of Cr(III) ions and has minimal activity on insulin receptors. [24] The apochromodulin is stored in insulin sensitive cells in the nucleus. When blood glucose levels rise, insulin is released into the bloodstream and binds to an external α-subunit of the insulin receptor, a transmembrane protein. [26] The insulin receptor consists of 2 extracellular α-subunits and 2 transmembrane β-subunits. [24] As soon as insulin binds to the insulin receptor, a conformational change in the receptor occurs, causing all 3 tyrosine residues (located in the β-subunits) to be phosphorylated. This activates the receptor and allows it to transmit the signal from insulin to the cell. [11] [24] [26] As mentioned above, absorbed chromium(III) picolinate eventually gives up Cr3+ to transferrin. In turn, transferrin transports Cr3+ to insulin sensitive cells (i.e. adipocytes) where it binds to apochromodulin to form holochromodulin. [24] Holochromodulin binds to the insulin receptor, which assists in maintaining the active conformation of the insulin receptor by prolonging the kinase activity of kinases or up-regulating the amount of insulin receptor mRNA levels, thus decreasing blood glucose levels. [11]

Experiments were able to show that chromium(III) was capable of up-regulating insulin-stimulated insulin signal transduction via affecting downstream molecules of the IR, as evidenced by enhanced levels of tyrosine phosphorylation of IRS-1, elevated Thr308 and Ser473 phosphorylation of Akt, and increased PI3-K activity in a variety of cellular and animal models. [29] The increased IRS-1 phosphorylation led to increased insulin receptor sensitivity while Akt and PI3-K led to enhanced GLUT4 translocation to the cell surface, thus causing greater uptake of glucose. [29]

It has also been shown that chromium(III) can alleviate insulin resistance by reducing endoplasmic reticulum (ER) stress. [29] ER stress is defined as an accumulation of misfolded and unfolded proteins in the ER lumen. [29] ER stress leads to stimulation of c-Jun terminal kinase (JNK), which in turn phosphorylates the serine residue of IRS, leading to suppression of insulin signaling cascade and less glucose uptake. [30] Experimental findings suggest that chromium inhibits ER stress and hence the suppression of insulin signaling is uplifted. [30] The exact mechanism is unknown. [30]

Oxidation of a Cys residue to sulfenic acid. Oxidation of a Cys residue to sulfenic acid by chromium species.jpg
Oxidation of a Cys residue to sulfenic acid.

Another way that Cr(III) may prolong the insulin receptor's kinase activity is through the oxidation of a critical active site cysteine residue on protein-tyrosine phosphatase 1B (PTP1B). Normally, PTP1B dephosphorylates phosphotyrosine residues by carrying out nucleophilic attack on the phosphate group via its cysteine residue, thus inactivating the insulin receptor. [31] This process removes the phosphate group from the tyrosine residue to form a Cys–S–PO32− group that is subsequently hydrolyzed by water to regenerate the cysteine residue, permitting for another round of action. [31] Research has shown that chromium(III) may in fact cause irreversible inhibition of PTP1B. It is thought that Cr(III) is converted to Cr(VI) or Cr(V) (through the action of oxidoreductases) which then oxidize the thiol of the cysteine residue on PTP1B to sulfenic acid, consequently rendering it unable to attack the phosphate group on phosphotyrosine. [32] However, this is only a plausible mechanism, and no direct evidence has been shown to support this hypothesis. [31] When the signal cascade is turned off, holochromodulin is eliminated in urine since the formation constant is too large to remove Cr(III) directly. [8] Experimental evidence has shown that the loss of chromodulin from cells is correlated with an increase in chromium concentrations in the urine after ingesting food rich in carbohydrates (i.e. glucose). [26]

Health claims and debates

Body weight

Chromium(III) picolinate has been marketed in the United States as an aid to body development for athletes and as a means of losing weight. Reviews have reported either no effect on either muscle growth or fat loss, [33] or else a modest but statistically significant -1.1 kg (2.4 lb) weight loss in trials longer than 12 weeks. [6] The European Food Safety Authority reviewed the literature and concluded that there was insufficient evidence to support a claim. [34]

Diabetes

There are claims that the picolinate form of chromium supplementation aids in reducing insulin resistance and improving glucose metabolism, particularly in type 2 diabetics, but reviews showed no association between chromium and glucose or insulin concentrations for non-diabetics, and inconclusive results for diabetics. [35] [36] The authors of the second review mentioned that chromium picolinate decreased HbA1c levels by 0.7% in type 2 diabetes patients, they observed that poor quality studies produced larger positive outcomes than higher quality studies. [36] [37] Two reviews concluded that chromium(III) picolinate may be more effective at lowering blood glucose levels compared to other chromium-containing dietary supplements. [36] [38]

In 2005, the U.S. Food and Drug Administration (FDA) approved a qualified health claim for chromium picolinate as a dietary supplement relating to insulin resistance and risk of type 2 diabetes. Any company wishing to make such a claim must use the exact wording: "One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain." As part of the petition review process, the FDA rejected other claims for reducing abnormally elevated blood sugar, risk of cardiovascular disease, risk of retinopathy or risk of kidney disease. [39] In 2006 the FDA added that the "relationship between chromium(III) picolinate intake and insulin resistance is highly uncertain". [40]

Variability of studies

There was no consistency observed in clinical results relating chromium(III) picolinate to adequate treatment of type 2 diabetes. This is due to the degree of glucose intolerance of patients that participate in the clinical studies. [10] Glucose intolerance is a gradient and the intensity is affected by ethnicity, degree of obesity, age, distribution of body fat and many other factors. [10] In some studies, low dosages of the supplement were given, however, a suitable amount of chromium(III) picolinate must be administered to a person before any appreciable drop in glucose levels is observed due to differing levels of insulin resistance. Another important point to mention is that diabetes is not always caused by glucose intolerance. [10] As mentioned before, Cr(III) has been shown to only influence glucose intolerance and not insulin levels. Furthermore, the environments in which the studies were performed were not consistent. The levels of stress, diets consumed by patients and patient genetics were variable among study subjects. [10] This is also true of the controls amongst different studies in which the subjects having diabetes were already being treated with a wide variety of antidiabetic drugs, which can reduce the effects of chromium on affecting insulin activity. [30] This could explain why animal studies tend to yield more positive results owing to the fact that these diabetic animals were not treated with antidiabetic drugs for the control group. [30] Also, as mentioned in the absorption and excretion section, the absorption/bioavailability of chromium(III) picolinate is influenced by the diet. Collectively, these different factors have contributed to the variability in the studies.

Safety and toxicity

Initial concerns were raised that chromium(III) picolinate is more likely to cause DNA damage and mutation than other forms of trivalent chromium, [41] but these results are also debated. [42] These concerns were based, in part, on studies in fruit flies, where chromium(III) picolinate supplementation generates chromosomal aberrations, impedes progeny development, [43] and causes sterility and lethal mutations. [44]

A study was published to assess the toxicity of Cr(III) picolinate on humans. [45] The researchers that conducted this study used previous knowledge that Cr(III) is reduced to Cr(II) by cellular reductants such as NADH or cysteine. [45] This reduced form of Cr(II) is shown to react with H2O2 to generate radical species which in turn oxidize DNA base pairs. [46] [47] With this knowledge in mind, the researchers administered ten women with 400 μg of chromium(III) picolinate a day for an eight-week period. [45] By measuring the amount of an oxidized DNA base pair, 5-hydroxymethyl uracil using antibody titers, the group could infer the amount of DNA base pair oxidation occurring in direct relation to chromium(III) picolinate. [45] The results of the study suggested that chromium(III) picolinate itself does not cause significant chromosomal damage in vivo. [45]

Generally speaking, it has been shown that chromium(III) picolinate is not toxic to humans. For most adults, it can be taken orally in doses up 1000 μg per day. [48] This low toxicity has generally been associated with low absorbance of Cr(III) in the body through the lungs, skin and gastrointestinal tract, [49] coupled with high excretion. Normally, 99% of chromium(III) taken can be recovered in the feces of the user. There have been isolated instances of chromium(III) supplementation leading to kidney failure, however this relationship is unclear and has yet to be tested. [50]

Regulation of chromium(III) picolinate

In 2004, the UK Food Standards Agency advised consumers to use other forms of trivalent chromium in preference to chromium(III) picolinate until specialist advice was received from the Committee on Mutagenicity. This was due to concerns raised by the Expert Group on Vitamins and Minerals that chromium(III) picolinate might be genotoxic (cause cancer). The committee also noted two case reports of kidney failure that might have been caused by this supplement and called for further research into its safety. [51] [52] In December 2004, the Committee on Mutagenicity published its findings, which concluded that "overall it can be concluded that the balance of the data suggest that chromium(III) picolinate should be regarded as not being mutagenic in vitro" and that "the available in-vivo tests in mammals with chromium(III) picolinate are negative". [53] Following these findings, the UK Food Standards Agency withdrew its advice to avoid chromium(III) picolinate, though it plans to keep its advice about chromium supplements under review. [54]

In 2010, chromium(III) picolinate was approved by Health Canada to be used in dietary supplements. Approved labeling statements include: a factor in the maintenance of good health, provides support for healthy glucose metabolism, helps the body to metabolize carbohydrates and helps the body to metabolize fats. [55]

Related Research Articles

<span class="mw-page-title-main">Chromium</span> Chemical element, symbol Cr and atomic number 24

Chromium is a chemical element; it has symbol Cr and atomic number 24. It is the first element in group 6. It is a steely-grey, lustrous, hard, and brittle transition metal.

<span class="mw-page-title-main">Insulin</span> Peptide hormone

Insulin is a peptide hormone produced by beta cells of the pancreatic islets encoded in humans by the insulin (INS) gene. It is considered to be the main anabolic hormone of the body. It regulates the metabolism of carbohydrates, fats and protein by promoting the absorption of glucose from the blood into liver, fat and skeletal muscle cells. In these tissues the absorbed glucose is converted into either glycogen via glycogenesis or fats (triglycerides) via lipogenesis, or, in the case of the liver, into both. Glucose production and secretion by the liver is strongly inhibited by high concentrations of insulin in the blood. Circulating insulin also affects the synthesis of proteins in a wide variety of tissues. It is therefore an anabolic hormone, promoting the conversion of small molecules in the blood into large molecules inside the cells. Low insulin levels in the blood have the opposite effect by promoting widespread catabolism, especially of reserve body fat.

<span class="mw-page-title-main">Insulin-like growth factor</span> Proteins similar to insulin that stimulate cell proliferation

The insulin-like growth factors (IGFs) are proteins with high sequence similarity to insulin. IGFs are part of a complex system that cells use to communicate with their physiologic environment. This complex system consists of two cell-surface receptors, two ligands, a family of seven high-affinity IGF-binding proteins, as well as associated IGFBP degrading enzymes, referred to collectively as proteases.

<span class="mw-page-title-main">Transferrin</span> Mammalian protein found in Homo sapiens

Transferrins are glycoproteins found in vertebrates which bind and consequently mediate the transport of iron (Fe) through blood plasma. They are produced in the liver and contain binding sites for two Fe3+ ions. Human transferrin is encoded by the TF gene and produced as a 76 kDa glycoprotein.

<span class="mw-page-title-main">Insulin receptor</span> Mammalian protein found in Homo sapiens

The insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of receptor tyrosine kinase. Metabolically, the insulin receptor plays a key role in the regulation of glucose homeostasis; a functional process that under degenerate conditions may result in a range of clinical manifestations including diabetes and cancer. Insulin signalling controls access to blood glucose in body cells. When insulin falls, especially in those with high insulin sensitivity, body cells begin only to have access to lipids that do not require transport across the membrane. So, in this way, insulin is the key regulator of fat metabolism as well. Biochemically, the insulin receptor is encoded by a single gene INSR, from which alternate splicing during transcription results in either IR-A or IR-B isoforms. Downstream post-translational events of either isoform result in the formation of a proteolytically cleaved α and β subunit, which upon combination are ultimately capable of homo or hetero-dimerisation to produce the ≈320 kDa disulfide-linked transmembrane insulin receptor.

<span class="mw-page-title-main">GSK-3</span> Class of enzymes

Glycogen synthase kinase 3 (GSK-3) is a serine/threonine protein kinase that mediates the addition of phosphate molecules onto serine and threonine amino acid residues. First discovered in 1980 as a regulatory kinase for its namesake, glycogen synthase (GS), GSK-3 has since been identified as a protein kinase for over 100 different proteins in a variety of different pathways. In mammals, including humans, GSK-3 exists in two isozymes encoded by two homologous genes GSK-3α (GSK3A) and GSK-3β (GSK3B). GSK-3 has been the subject of much research since it has been implicated in a number of diseases, including type 2 diabetes, Alzheimer's disease, inflammation, cancer, addiction and bipolar disorder.

<span class="mw-page-title-main">Chromium(III) chloride</span> Chemical compound

Chromium(III) chloride (also called chromic chloride) is an inorganic chemical compound with the chemical formula CrCl3. It forms several hydrates with the formula CrCl3·nH2O, among which are hydrates where n can be 5 (chromium(III) chloride pentahydrate CrCl3·5H2O) or 6 (chromium(III) chloride hexahydrate CrCl3·6H2O). The anhydrous compound with the formula CrCl3 are violet crystals, while the most common form of the chromium(III) chloride are the dark green crystals of hexahydrate, CrCl3·6H2O. Chromium chlorides find use as catalysts and as precursors to dyes for wool.

Chromium deficiency is described as the consequence of an insufficient dietary intake of the mineral chromium. Chromium was first proposed as an essential element for normal glucose metabolism in 1959, but its biological function has not been identified. Cases of deficiency were described in people who received all of their nutrition intravenously for long periods of time.

Glucose transporter type 4 (GLUT4), also known as solute carrier family 2, facilitated glucose transporter member 4, is a protein encoded, in humans, by the SLC2A4 gene. GLUT4 is the insulin-regulated glucose transporter found primarily in adipose tissues and striated muscle. The first evidence for this distinct glucose transport protein was provided by David James in 1988. The gene that encodes GLUT4 was cloned and mapped in 1989.

<span class="mw-page-title-main">Liver X receptor</span> Nuclear receptor

The liver X receptor (LXR) is a member of the nuclear receptor family of transcription factors and is closely related to nuclear receptors such as the PPARs, FXR and RXR. Liver X receptors (LXRs) are important regulators of cholesterol, fatty acid, and glucose homeostasis. LXRs were earlier classified as orphan nuclear receptors, however, upon discovery of endogenous oxysterols as ligands they were subsequently deorphanized.

Iron-binding proteins are carrier proteins and metalloproteins that are important in iron metabolism and the immune response. Iron is required for life.

<span class="mw-page-title-main">Glucagon-like peptide-1 receptor</span> Receptor activated by peptide hormone GLP-1

The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level by enhancing insulin secretion. In humans it is synthesised by the gene GLP1R, which is present on chromosome 6. It is a member of the glucagon receptor family of GPCRs. GLP1R is composed of two domains, one extracellular (ECD) that binds the C-terminal helix of GLP-1, and one transmembrane (TMD) domain that binds the N-terminal region of GLP-1. In the TMD domain there is a fulcrum of polar residues that regulates the biased signaling of the receptor while the transmembrane helical boundaries and extracellular surface are a trigger for biased agonism.

<span class="mw-page-title-main">IGFBP3</span> Protein-coding gene in the species Homo sapiens

Insulin-like growth factor-binding protein 3, also known as IGFBP-3, is a protein that in humans is encoded by the IGFBP3 gene. IGFBP-3 is one of six IGF binding proteins that have highly conserved structures and bind the insulin-like growth factors IGF-1 and IGF-2 with high affinity. IGFBP-7, sometimes included in this family, shares neither the conserved structural features nor the high IGF affinity. Instead, IGFBP-7 binds IGF1R, which blocks IGF-1 and IGF-2 binding, resulting in apoptosis.

<span class="mw-page-title-main">PTPN1</span> Protein-coding gene in the species Homo sapiens

Tyrosine-protein phosphatase non-receptor type 1 also known as protein-tyrosine phosphatase 1B (PTP1B) is an enzyme that is the founding member of the protein tyrosine phosphatase (PTP) family. In humans it is encoded by the PTPN1 gene. PTP1B is a negative regulator of the insulin signaling pathway and is considered a promising potential therapeutic target, in particular for treatment of type 2 diabetes. It has also been implicated in the development of breast cancer and has been explored as a potential therapeutic target in that avenue as well.

<span class="mw-page-title-main">Forkhead box protein O1</span> Protein

Forkhead box protein O1 (FOXO1), also known as forkhead in rhabdomyosarcoma (FKHR), is a protein that in humans is encoded by the FOXO1 gene. FOXO1 is a transcription factor that plays important roles in regulation of gluconeogenesis and glycogenolysis by insulin signaling, and is also central to the decision for a preadipocyte to commit to adipogenesis. It is primarily regulated through phosphorylation on multiple residues; its transcriptional activity is dependent on its phosphorylation state.

Chromium toxicity refers to any poisonous toxic effect in an organism or cell that results from exposure to specific forms of chromium—especially hexavalent chromium. Hexavalent chromium and its compounds are toxic when inhaled or ingested. Trivalent chromium is a trace mineral that is essential to human nutrition. There is a hypothetical risk of genotoxicity in humans if large amounts of trivalent chromium were somehow able to enter living cells, but normal metabolism and cell function prevent this.

Low-molecular-weight chromium-binding substance (LMWCr; also known as chromodulin) is an oligopeptide that seems to transport chromium in the body. It consists of four amino acid residues; aspartate, cysteine, glutamate, and glycine, bonded with four (Cr3+) centers. It interacts with the insulin receptor, by prolonging kinase activity through stimulating the tyrosine kinase pathway, thus leading to improved glucose absorption. and has been confused with glucose tolerance factor.

Phonemic neurological hypochromium therapy (PNHT) is a technique that uses insemination devices to implement chromium (Cr3+) into the hypothalamic regions of the brain. It has been proposed by Dr. Nicole Kim to offset delayed phonemic awareness in children between the ages of 3 and 8. The causes of delayed phonemic awareness have been linked to an inability to break down chromium triastenitephosphate. PNHT has been successfully implemented into in vivo mice with some controversial side effects, including; polydactyly, regurgitation, fatigue, and nausea. While Russia, Poland, and Ukraine have approved this procedure, the United States Food and Drug Administration (USFDA) has not yet granted its approval.

The insulin transduction pathway is a biochemical pathway by which insulin increases the uptake of glucose into fat and muscle cells and reduces the synthesis of glucose in the liver and hence is involved in maintaining glucose homeostasis. This pathway is also influenced by fed versus fasting states, stress levels, and a variety of other hormones.

Chromium is claimed to be an essential element involved in the regulation of blood glucose levels within the body. More recent reviews have questioned this, however.

References

  1. ↑ Preuss, H. G.; Echard, B.; Perricone, N. V.; Bagchi, D.; Yasmin, T.; Stohs, S. J. (2008). "Comparing metabolic effects of six different commercial trivalent chromium compounds". Journal of Inorganic Biochemistry. 102 (11): 1986–1990. doi:10.1016/j.jinorgbio.2008.07.012. PMID   18774175.
  2. ↑ "The Nutrition Source: Chromium". School of Public Health, Harvard University.
  3. ↑ Review of Chromium Archived February 7, 2012, at the Wayback Machine Expert Group on Vitamins and Minerals Review of Chromium, 12 August 2002
  4. ↑ Stearns DM (2000). "Is chromium a trace essential metal?". BioFactors. 11 (3): 149–62. doi:10.1002/biof.5520110301. PMID   10875302. S2CID   19417496.
  5. 1 2 3 4 Vincent, John (2010). "Chromium: celebrating 50 years as an essential element?". Dalton Transactions. 39 (16): 3787–3794. doi:10.1039/B920480F. PMID   20372701.
  6. 1 2 Tian, H; Guo, X; Wang, X; He, Z; Sun, R; Ge, S; Zhang, Z (2013). "Chromium picolinate supplementation for overweight or obese adults". The Cochrane Database of Systematic Reviews. 2013 (11): CD010063. doi:10.1002/14651858.CD010063.pub2. PMC   7433292 . PMID   24293292. CD010063.
  7. 1 2 3 4 Levina, Aviva; Lay, Peter (2008). "Chemical Properties and Toxcity of Chromium (III) Nutritional Supplements". Chemical Research in Toxicology. 21 (3): 563–571. doi:10.1021/tx700385t. PMID   18237145.
  8. 1 2 3 4 5 6 7 8 9 Feng, Weiyue (2007). "Chapter 6 – The Transport of chromium (III) in the body: Implications for Function" (PDF). In Vincent, John (ed.). The Nutritional Biochemistry of Chromium (III). Amsterdam: Elsevier B.V. pp. 121–137. ISBN   978-0444530714 . Retrieved 20 March 2015.[ permanent dead link ]
  9. 1 2 Cefalu, William; Hu, Frank (2004). "Role of Chromium in Human Health and in Diabetes". Diabetes Care. 27 (11): 2741–2751. doi: 10.2337/diacare.27.11.2741 . PMID   15505017 . Retrieved 20 March 2015.
  10. 1 2 3 4 5 6 Anderson, Richard (1998). "Chromium, Glucose Intolerance and Diabetes". Journal of the American College of Nutrition. 17 (6): 548–555. doi:10.1080/07315724.1998.10718802. PMID   9853533. S2CID   19532052.
  11. 1 2 3 4 Vincent, John (2004). "Recent advances in the nutritional biochemistry of trivalent chromium". Proceedings of the Nutrition Society. 63 (1): 41–47. doi: 10.1079/PNS2003315 . PMID   15070438.
  12. 1 2 3 4 5 Vincent, John (2001). "The Bioinorganic Chemistry of Chromium (III)". Polyhedron. 20 (1–2): 1–26. doi:10.1016/S0277-5387(00)00624-0.
  13. 1 2 3 Abou–Gamra, Zeinab; Abdel–Messih, Michel (2014). "Correlation of thermal and spectral properties of chromium(III) picolinate complex and kinetic study of its thermal degradation". Journal of Thermal Analysis and Calorimetry. 117 (2): 993–1000. doi:10.1007/s10973-014-3768-5. S2CID   93050541.
  14. 1 2 3 4 5 Parajón–Costa, Beatriz; Wagner, Claudia; Baran, Enrique (2003). "Voltammetric and Spectroscopic Study of Chromium(III)/Picolinate Complexes". Zeitschrift für Anorganische und Allgemeine Chemie. 629 (6): 1085–1090. doi:10.1002/zaac.200300050.
  15. 1 2 3 Stearns, Diane; Armstrong, William (1992). "Mononuclear and binuclear chromium(III) picolinate complexes". Inorganic Chemistry. 31 (25): 5178–5184. doi:10.1021/ic00051a007.
  16. 1 2 3 4 Hakimi, Mohammad (2013). "Structural and Spectral Characterization of a Chromium (III) Picolinate Complex: Introducing a New Redox Reaction". Journal of the Korean Chemical Society. 57 (6): 721–725. doi: 10.5012/jkcs.2013.57.6.721 . Retrieved 1 April 2015.
  17. 1 2 Lukaski, Henry (2007). "Chapter 4 –Effects of Chromium(III) as a nutritional supplement" (PDF). In Vincent, John (ed.). The Nutritional Biochemistry of Chromium (III). Amsterdam: Elsevier B.V. pp. 57–70. ISBN   978-0444530714 . Retrieved 20 March 2015.[ permanent dead link ]
  18. 1 2 3 Laschinsky, Niels; Kottwitz, Karin; Freund, Barbara; Dresow, bernd; Fischer, Roland; Nielsen, Peter (2012). "Bioavailability of chromium(III)-supplements in rats and humans". BioMetals. 25 (5): 1051–1060. doi:10.1007/s10534-012-9571-5. PMID   22814636. S2CID   1533593.
  19. 1 2 3 4 5 6 7 Debski, B.; Goniewicz, M.; Krzyzowskal, M.; Lewicka, A.; Lewickil, S.; Niemcewiz, M.; Zdanowskil, R. (2014). "The role of Chromium III in the organism and its possible use in diabetes and obesity treatment". Annals of Agricultural and Environmental Medicine. 21 (2): 331–335. doi: 10.5604/1232-1966.1108599 . PMID   24959784.
  20. 1 2 3 4 5 6 7 8 Vincent, John (2015). "Is the Pharmacological Mode of Action of Chromium (III) as a secondary messenger?". Biological Trace Element Research. 166 (1): 7–12. doi:10.1007/s12011-015-0231-9. PMID   25595680. S2CID   16895342.
  21. 1 2 3 4 5 6 Quarles, C.; Marcus, R.; Brumaghim, Julia (2011). "Competitive binding of Fe3+, Cr3+, and Ni2+ to transferrin". Journal of Biological Inorganic Chemistry. 16 (6): 913–921. doi:10.1007/s00775-011-0792-9. PMID   21678080. S2CID   24302252.
  22. 1 2 Vincent, John (2012). "The binding and transport of alternative metals by transferrin". Biochimica et Biophysica Acta (BBA) - General Subjects. 1820 (3): 362–378. doi:10.1016/j.bbagen.2011.07.003. PMID   21782896.
  23. ↑ Levina, Aviva; Pham, T. H. Nguyen; Lay, Peter A. (2016-05-01). "Binding of Chromium(III) to Transferrin Could be Involved in Detoxification of Dietary Chromium(III) Rather Than Transport of an Essential Trace Element". Angewandte Chemie International Edition. 55 (28): 8104–8107. doi: 10.1002/anie.201602996 . ISSN   1521-3773. PMID   27197571.
  24. 1 2 3 4 5 6 7 Vincent, John (2012). "Biochemical Mechanisms". In Vincent, John (ed.). The Bioinorganic Chemistry of Chromium. Chichester, UK: John Wiley & Sons. pp. 125–167. doi:10.1002/9781118458891.ch6. ISBN   978-0470664827.
  25. ↑ Viera M, Davis-McGibony CM (2008). "Isolation and characterization of low-molecular-weight chromium-binding substance (LMWCr) from chicken liver". Protein J. 27 (6): 371–375. doi:10.1007/s10930-008-9146-z. PMID   18769887. S2CID   32564084.
  26. 1 2 3 4 Vincent, John (2000). "The Biochemistry of Chromium". The Journal of Nutrition. 130 (4): 715–718. doi: 10.1093/jn/130.4.715 . PMID   10736319.
  27. ↑ Clodfelder BJ, Emamaullee J, Hepburn DD, Chakov NE, Nettles HS, Vincent JB (2001). "The trail of chromium(III) in vivo from the blood to the urine: the roles of transferrin and chromodulin". J. Biol. Inorg. Chem. 6 (5–6): 608–617. doi:10.1007/s007750100238. PMID   11472024. S2CID   8956685.
  28. ↑ Vincent JB (1994). "Relationship between glucose tolerance factor and low-molecular-weight chromium-binding substance" (PDF). J. Nutr. 124 (1): 117–9. doi:10.1093/jn/124.1.117. PMID   8283288.
  29. 1 2 3 4 Kitamura, Masanori (2008). "Endoplasmic reticulum stress and unfolded protein response in renal pathophysiology: Janus faces". American Journal of Physiology. 295 (2): 323–334. doi:10.1152/ajprenal.00050.2008. PMID   18367660.
  30. 1 2 3 4 5 Hua, Yinan; Clark, Suzanne; Ren, Jun; Sreejayan, Nair (2012). "Molecular Mechanisms of Chromium in Alleviating Insulin Resistance". Journal of Nutritional Biochemistry. 23 (4): 313–319. doi:10.1016/j.jnutbio.2011.11.001. PMC   3308119 . PMID   22423897.
  31. 1 2 3 Tonks, Nicholas (2003). "PTP1B: From the sidelines to the front lines!". FEBS Letters. 546 (1): 140–148. doi: 10.1016/S0014-5793(03)00603-3 . PMID   12829250. S2CID   21205538.
  32. ↑ Levina, Aviva (2011). "Metal based anti-diabetic drugs: advances and challenges". Dalton Transactions. 40 (44): 11675–1686. doi:10.1039/C1DT10380F. PMID   21750828.
  33. ↑ Vincent J.B.; Sack, DA; Roffman, M; Finch, M; Komorowski, JR (2003). "The potential value and toxicity of chromium picolinate as a nutritional supplement, weight loss agent and muscle development agent". Sports Medicine. 33 (3): 213–230. doi:10.2165/00007256-200333030-00004. PMID   12656641. S2CID   9981172.
  34. ↑ "Scientific Opinion on the substantiation of health claims related to chromium and contribution to normal macronutrient metabolism (ID 260, 401, 4665, 4666, 4667), maintenance of normal blood glucose concentrations (ID 262, 4667), contribution to the maintenance or achievement of a normal body weight (ID 339, 4665, 4666), and reduction of tiredness and fatigue (ID 261) pursuant to Article 13(1) of Regulation (EC) No 1924/2006". EFSA Journal. 8 (10). 2010. doi: 10.2903/j.efsa.2010.1732 .
  35. ↑ Althuis MD, Jordan NE, Ludington EA, Wittes JT (1 July 2002). "Glucose and insulin responses to dietary chromium supplements: a meta-analysis". American Journal of Clinical Nutrition. 76 (1): 148–155. doi: 10.1093/ajcn/76.1.148 . PMID   12081828.
  36. 1 2 3 Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG (2007). "Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials". Diabetes Care. 30 (8): 2154–2163. doi: 10.2337/dc06-0996 . PMID   17519436.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  37. ↑ Suksomboon, N.; Poolsup, N.; Yuwanakom, A. (2014). "Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes". Journal of Clinical Pharmacy and Therapeutics. 39 (3): 292–306. doi: 10.1111/jcpt.12147 . PMID   24635480. S2CID   22326435.
  38. ↑ Broadhurst CL, Domenico P (December 2006). "Clinical studies on chromium picolinate supplementation in diabetes mellitus – a review". Diabetes Technol. Ther. 8 (6): 677–87. doi:10.1089/dia.2006.8.677. PMID   17109600.
  39. ↑ Qualified Health Claims: Letter of Enforcement Discretion – Chromium Picolinate and Insulin Resistance (Docket No. 2004Q-0144) (2005) U.S. Food and Drug Administration.
  40. ↑ Trumbo PR, Ellwood KC (August 2006). "Chromium picolinate intake and risk of type 2 diabetes: an evidence-based review by the United States Food and Drug Administration". Nutr. Rev. 64 (8): 357–63. doi: 10.1111/j.1753-4887.2006.tb00220.x . PMID   16958312.
  41. ↑ Chaudhary S, Pinkston J, Rabile MM, Van Horn JD (2005). "Unusual reactivity in a commercial chromium supplement compared to baseline DNA cleavage with synthetic chromium complexes". Journal of Inorganic Biochemistry. 99 (3): 787–794. doi:10.1016/j.jinorgbio.2004.12.009. PMID   15708800.
  42. ↑ Hininger I, Benaraba R, Osman M, Faure H, Marie Roussel A, Anderson RA (2007). "Safety of trivalent chromium complexes: no evidence for DNA damage in human HaCaT keratinocytes". Free Radic. Biol. Med. 42 (12): 1759–65. doi:10.1016/j.freeradbiomed.2007.02.034. PMID   17512455.
  43. ↑ Stallings DM, Hepburn DD, Hannah M, Vincent JB, O'Donnell J (2006). "Nutritional supplement chromium picolinate generates chromosomal aberrations and impedes progeny development in Drosophila melanogaster". Mutat. Res. 610 (1–2): 101–13. doi:10.1016/j.mrgentox.2006.06.019. PMID   16887379.
  44. ↑ Hepburn DD, Xiao J, Bindom S, Vincent JB, O'Donnell J (2003). "Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster". Proc. Natl. Acad. Sci. U.S.A. 100 (7): 3766–71. doi: 10.1073/pnas.0636646100 . PMC   152996 . PMID   12649323.
  45. 1 2 3 4 5 Kato, Ikuko; Vogelman, Joseph; Dilman, Vladimir; Karkoszka, Jerzy; Frenkel, Krystyna; Durr, Nancy; Orentreich, Norman; Toniolo, Paolo (1998). "Effect of supplementation with chromium picolinate on antibody titers to 5–hydroxymethyl uracil". European Journal of Epidemiology. 14 (6): 621–626. doi:10.1023/A:1007442203258. PMID   9794131. S2CID   19071972.
  46. ↑ Tsou, Tsui–Chun; Chen, Chiu–lan; Liu, Tsung–Yun; Yang, Jia-Ling (1996). "Induction of 8-hydroxydeoxyguanosine in DNA by chromium(III) plus hydrogen peroxide and its prevention by scavengers" (PDF). Carcinogenesis. 17 (1): 103–108. doi: 10.1093/carcin/17.1.103 . PMID   8565117 . Retrieved 20 March 2015.
  47. ↑ Ozawa, T.; Hanaki, A. (1990). "Spin-trapping studies on the reactions of Cr(III) with hydrogen peroxide in the presence of biological reductants: is Cr(III) non-toxic?". Biochemistry International. 22 (2): 343–352. PMID   1965278.
  48. ↑ Jeejeebhoy, Khursheed (2009). "The Role of Chromium in Nutrition and Therapeutics and As a Potential Toxin". Nutrition Reviews. 57 (11): 329–335. doi: 10.1111/j.1753-4887.1999.tb06909.x . PMID   10628183.
  49. ↑ Fairhurst, S.; Minty, C. (1989). The toxicity of chromium and inorganic chromium compounds. Toxicity Review; 21. London: H.M.S.O. pp. 1–243. ISBN   978-0118855211.
  50. ↑ Wasser, Walter; Feldman, Nathaniel; D'Agati, Vivette (1997). "Chronic Renal Failure after Ingestion of Over-the-Counter Chromium Picolinate". Annals of Internal Medicine. 126 (5): 410. doi:10.7326/0003-4819-126-5-199703010-00019. PMID   9054292. S2CID   27418296.
  51. ↑ Safe Upper Levels for Vitamins and Minerals Archived 2008-07-04 at the Wayback Machine Food Standards Agency – May 2003
  52. ↑ Risk assessment: Chromium Expert Group on Vitamins and Minerals, 2003
  53. ↑ Statement on the Mutagenicity of Trivalent Chromium and Chromium Picolinate Archived 2008-05-16 at the Wayback Machine COM/04/S3 - December 2004
  54. ↑ Agency revises chromium picolinate advice Food Standards Agency - 13 December 2004
  55. ↑ "Monograph: Chromium (from Chromium picolinate)". Health Canada. December 9, 2009. Retrieved March 24, 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.